The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Oligodendroglioma

A glioma defined by IDH mutation and 1p/19q co-deletion with relatively favorable prognosis among gliomas.

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Onkoloji department. Book Appointment →

What is Oligodendroglioma?

Oligodendroglioma is a glioma believed to arise from oligodendrocytes or their precursors. The 2021 WHO classification of CNS tumors defines oligodendroglioma by the presence of both IDH mutation (IDH1 or IDH2) and 1p/19q whole-arm co-deletion. These molecular features are now required for diagnosis, replacing histological-only classification.

Oligodendrogliomas are graded as WHO grade 2 (well-differentiated) or grade 3 (anaplastic) based on histological features such as mitotic activity, microvascular proliferation, and necrosis. They typically occur in adults aged 30-50, most commonly in the frontal lobes. The classic histological appearance includes 'fried-egg' cells with perinuclear halos and a 'chicken-wire' vascular pattern, but these features are unreliable; molecular testing is required.

Oligodendrogliomas are particularly responsive to radiation and chemotherapy compared to other gliomas. The standard treatment for newly diagnosed grade 3 oligodendroglioma is maximal safe resection followed by radiation and PCV chemotherapy (procarbazine, lomustine, vincristine), which has shown survival benefit. Grade 2 tumors may be observed after resection or treated similarly. Median survival exceeds 10-15 years for many patients.

Symptoms

Seizures (most common presenting symptom, often the only initial sign)
Headache (progressive)
Cognitive or personality changes
Focal neurological deficits depending on location
Memory and attention problems
Mood changes (frontal lobe predilection)
Visual disturbances
Speech difficulties (left hemisphere)
Motor weakness or sensory changes
Symptoms over months to years (slow growth typical)
Sometimes incidental finding on imaging for other reasons
Long history before diagnosis common

Risk Factors

Adult age 30-50 years
Male sex (slight predominance)
No proven environmental risk factors
Prior cranial radiation (rare)
Most cases sporadic without identifiable cause
Genetic syndromes are rarely associated
Unlike many cancers, no clear modifiable risk factors

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • First-time seizure in adulthood
  • New onset persistent headache
  • Progressive neurological symptoms
  • Cognitive or personality changes
  • Focal weakness, sensory changes, or visual problems
  • Speech difficulties
  • Memory problems
  • Any concerning brain imaging finding

Treatment Methods

01
Multidisciplinary neuro-oncology team
02
MRI brain with contrast for evaluation
03
Maximal safe surgical resection (gross total when feasible)
04
Tissue diagnosis with mandatory molecular testing: IDH, 1p/19q, MGMT, TERT
05
Diagnosis requires both IDH mutation AND 1p/19q co-deletion
06
Grade 2 oligodendroglioma: observation, radiation, or RT plus PCV based on risk factors
07
Grade 3 (anaplastic) oligodendroglioma: radiation plus PCV chemotherapy (standard of care)
08
PCV regimen: procarbazine, lomustine (CCNU), vincristine — 6 cycles
09
Temozolomide: alternative to PCV (less toxic but less evidence)
10
IDH inhibitors (vorasidenib): for select grade 2 IDH-mutant gliomas with measurable disease
11
Recurrent disease: temozolomide, lomustine, bevacizumab, reoperation, reirradiation
12
Anticonvulsant therapy: levetiracetam preferred (no enzyme induction)
13
Cognitive rehabilitation: address radiation and chemotherapy effects
14
Long-term surveillance: serial MRI every 3-6 months
15
Neuropsychological testing: baseline and follow-up
16
Quality of life optimization: work, driving (seizure-free period required), social
17
Genetic counseling if syndrome suspected
18
Late effect monitoring: secondary cancers, cognitive decline, vasculopathy
19
Clinical trial enrollment when appropriate

Which Department to Visit?

You can visit our Onkoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Onkoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.